Ichor Biologics is dedicated to the development and commercialization of therapeutic antibodies that target novel pathways for the treatment of infectious and autoimmune diseases
Ichor Biologics has gathered a team of world-class researchers with expertise in immunobiology, infectious disease and cancer biology in order to develop novel antibody therapeutics. Our team has recently identified several critical pathways involved in the regulation and control inflammation and T cell activation. In addition, we have developed high-throughput screening platforms for the identification and isolation of antibodies against Dengue, Ebola and Hanta viruses. We are currently, in the initial phases of validating targets and measuring the efficacy of several potential monoclonal antibodies therapies.